单中心试验中花生过敏患者口服花生免疫治疗的安全性。
The safety of peanut oral immunotherapy in peanut-allergic subjects in a single-center trial.
机构信息
Division of Immunology and Allergy, Stanford University, Stanford, CA, USA.
出版信息
Int Arch Allergy Immunol. 2012;159(2):179-82. doi: 10.1159/000336391. Epub 2012 Jun 1.
Abstract
BACKGROUND
Peanut allergy is the leading cause of food-related anaphylaxis, and accidental exposures are common. Oral immunotherapy (OIT) has been posited as a potential treatment.
METHODS
Patients aged 3-65 years with peanut-specific IgE ≥7 kU/l and/or a positive skin prick test with a history of an allergic reaction to peanut were recruited to undergo an OIT protocol. All adverse reactions were recorded by research staff or patients in real time.
RESULTS
Twenty-four patients received 6,662 doses. Symptoms were mostly mild (84%), and only 3 severe gastrointestinal reactions required the administration of epinephrine. Abdominal pain was the most common reaction, followed by oropharyngeal and lip pruritus. Respiratory symptoms were rare.
CONCLUSIONS
In this trial of OIT in adults and children, most reactions were mild.
摘要
背景
花生过敏是食物相关过敏反应的主要原因，且意外接触较为常见。口服免疫治疗（OIT）被认为是一种潜在的治疗方法。
方法
招募年龄在 3-65 岁之间、花生特异性 IgE≥7 kU/l 且/或对花生有过敏反应史的皮试阳性的患者，进行 OIT 方案。所有不良反应均由研究人员或患者实时记录。
结果
24 例患者接受了 6662 剂治疗。症状大多为轻度（84%），仅有 3 例严重胃肠道反应需要使用肾上腺素。腹痛是最常见的反应，其次是口腔和唇部瘙痒。呼吸道症状少见。
结论
在这项成人和儿童 OIT 的试验中，大多数反应为轻度。
相似文献
1
The safety of peanut oral immunotherapy in peanut-allergic subjects in a single-center trial.单中心试验中花生过敏患者口服花生免疫治疗的安全性。
Int Arch Allergy Immunol. 2012;159(2):179-82. doi: 10.1159/000336391. Epub 2012 Jun 1.
2
Allergen-specific oral immunotherapy for peanut allergy.针对花生过敏的过敏原特异性口服免疫疗法。
Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD009014. doi: 10.1002/14651858.CD009014.pub2.
3
First Real-World Safety Analysis of Preschool Peanut Oral Immunotherapy.首个幼儿园花生口服免疫治疗的真实世界安全性分析。
J Allergy Clin Immunol Pract. 2019 Nov-Dec;7(8):2759-2767.e5. doi: 10.1016/j.jaip.2019.04.010. Epub 2019 Apr 17.
4
A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy.一项关于舌下免疫疗法与口服免疫疗法治疗花生过敏的随机、双盲、安慰剂对照试验性研究。
J Allergy Clin Immunol. 2015 May;135(5):1275-82.e1-6. doi: 10.1016/j.jaci.2014.11.005. Epub 2014 Dec 18.
5
Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.益生菌花生口服免疫治疗与口服免疫治疗和安慰剂在澳大利亚花生过敏儿童中的比较（PPOIT-003）：一项多中心、随机、2b 期试验。
Lancet Child Adolesc Health. 2022 Mar;6(3):171-184. doi: 10.1016/S2352-4642(22)00006-2. Epub 2022 Feb 4.
6
Feasibility of desensitizing children highly allergic to peanut by high-dose oral immunotherapy.通过高剂量口服免疫疗法使对花生高度过敏的儿童脱敏的可行性。
Allergy. 2019 Feb;74(2):337-348. doi: 10.1111/all.13604. Epub 2018 Oct 8.
7
Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study.口服免疫治疗花生过敏的持续疗效（POISED 研究）：一项大型、随机、双盲、安慰剂对照、2 期研究。
Lancet. 2019 Oct 19;394(10207):1437-1449. doi: 10.1016/S0140-6736(19)31793-3. Epub 2019 Sep 12.
8
Safety of a peanut oral immunotherapy protocol in children with peanut allergy.花生过敏儿童的花生口服免疫疗法方案的安全性。
J Allergy Clin Immunol. 2009 Aug;124(2):286-91, 291.e1-6. doi: 10.1016/j.jaci.2009.03.045. Epub 2009 May 27.
9
Clinical efficacy and immune regulation with peanut oral immunotherapy.花生口服免疫疗法的临床疗效与免疫调节
J Allergy Clin Immunol. 2009 Aug;124(2):292-300, 300.e1-97. doi: 10.1016/j.jaci.2009.05.022. Epub 2009 Jul 3.
10
Oral immunotherapy for peanut allergy: multipractice experience with epinephrine-treated reactions.口服免疫疗法治疗花生过敏：接受肾上腺素治疗的过敏反应的多实践经验。
J Allergy Clin Immunol Pract. 2014 Jan-Feb;2(1):91-6. doi: 10.1016/j.jaip.2013.10.001.
引用本文的文献
1
Transcriptional changes in peanut-specific CD4+ T cells over the course of oral immunotherapy.口服免疫治疗过程中花生特异性 CD4+T 细胞的转录变化。
Clin Immunol. 2020 Oct;219:108568. doi: 10.1016/j.clim.2020.108568. Epub 2020 Aug 9.
2
Adverse events associated with peanut oral immunotherapy in children - a systematic review and meta-analysis.儿童花生口服免疫治疗相关不良事件的系统评价和荟萃分析。
Sci Rep. 2020 Jan 20;10(1):659. doi: 10.1038/s41598-019-56961-3.
3
GRADE-ing the Benefit/Risk Equation in Food Immunotherapy.评估食物免疫治疗中获益/风险比。
Curr Allergy Asthma Rep. 2019 Apr 25;19(6):30. doi: 10.1007/s11882-019-0862-6.
4
Dietary Supplementation with Nondigestible Oligosaccharides Reduces Allergic Symptoms and Supports Low Dose Oral Immunotherapy in a Peanut Allergy Mouse Model.膳食补充不可消化低聚糖可减轻过敏症状并支持低剂量口服免疫治疗花生过敏小鼠模型。
Mol Nutr Food Res. 2018 Oct;62(20):e1800369. doi: 10.1002/mnfr.201800369. Epub 2018 Aug 31.
5
Food-Induced Anaphylaxis: an Update.食物诱导性过敏反应：最新进展。
Curr Allergy Asthma Rep. 2018 Jun 14;18(8):41. doi: 10.1007/s11882-018-0795-5.
6
Novel baseline predictors of adverse events during oral immunotherapy in children with peanut allergy.花生过敏儿童口服免疫治疗期间不良事件的新型基线预测指标。
J Allergy Clin Immunol. 2017 Mar;139(3):882-888.e5. doi: 10.1016/j.jaci.2016.07.030. Epub 2016 Sep 5.
7
Current opinion and review on peanut oral immunotherapy.关于花生口服免疫疗法的当前观点与综述
Hum Vaccin Immunother. 2014;10(10):3017-21. doi: 10.4161/hv.32190.
8
Oral immunotherapy for the treatment of food allergy.口服免疫疗法治疗食物过敏。
Hum Vaccin Immunother. 2014;10(8):2295-302. doi: 10.4161/hv.29233.
9
Diagnosis and management of food allergies: new and emerging options: a systematic review.食物过敏的诊断与管理：新出现的选择：一项系统综述
J Asthma Allergy. 2014 Oct 24;7:141-64. doi: 10.2147/JAA.S49277. eCollection 2014.
10
Emerging therapies for food allergy.食物过敏的新兴疗法。
J Clin Invest. 2014 May;124(5):1880-6. doi: 10.1172/JCI72061. Epub 2014 May 1.
本文引用的文献
1
A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response.花生口服免疫治疗的随机对照研究：临床脱敏和过敏反应的调节。
J Allergy Clin Immunol. 2011 Mar;127(3):654-60. doi: 10.1016/j.jaci.2010.12.1111.
2
Epidemiology of food allergy.食物过敏的流行病学。
J Allergy Clin Immunol. 2011 Mar;127(3):594-602. doi: 10.1016/j.jaci.2010.11.044. Epub 2011 Jan 13.
3
Frequency of US emergency department visits for food-related acute allergic reactions.美国急诊科因食物相关急性过敏反应就诊的频率。
J Allergy Clin Immunol. 2011 Mar;127(3):682-3. doi: 10.1016/j.jaci.2010.10.040. Epub 2010 Dec 16.
4
Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel.美国食物过敏诊断与管理指南：NIAID 赞助专家组报告。
J Allergy Clin Immunol. 2010 Dec;126(6 Suppl):S1-58. doi: 10.1016/j.jaci.2010.10.007.
5
Office-based oral immunotherapy for food allergy is safe and effective.基于诊所的食物过敏口服免疫疗法安全有效。
J Allergy Clin Immunol. 2011 Jan;127(1):290-1; author reply 291-2. doi: 10.1016/j.jaci.2010.08.052. Epub 2010 Oct 30.
6
Oral immunotherapy: ready for prime time?口服免疫疗法：准备好进入黄金时代了吗？
J Allergy Clin Immunol. 2011 Jan;127(1):289-90; author reply 291-2. doi: 10.1016/j.jaci.2010.08.053. Epub 2010 Oct 30.
7
Peanut oral immunotherapy is not ready for clinical use.花生口服免疫治疗尚未准备好用于临床。
J Allergy Clin Immunol. 2010 Jul;126(1):31-2. doi: 10.1016/j.jaci.2010.05.012.
8
Oral peanut immunotherapy in children with peanut anaphylaxis.儿童花生过敏的口服花生免疫治疗。
J Allergy Clin Immunol. 2010 Jul;126(1):83-91.e1. doi: 10.1016/j.jaci.2010.04.030. Epub 2010 Jun 12.
9
Food allergy among children in the United States.美国儿童中的食物过敏情况。
Pediatrics. 2009 Dec;124(6):1549-55. doi: 10.1542/peds.2009-1210. Epub 2009 Nov 16.
10
Clinical efficacy and immune regulation with peanut oral immunotherapy.花生口服免疫疗法的临床疗效与免疫调节
J Allergy Clin Immunol. 2009 Aug;124(2):292-300, 300.e1-97. doi: 10.1016/j.jaci.2009.05.022. Epub 2009 Jul 3.
Zotero 插件